Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models

Assay and Drug Development Technologies

Volumn 2, Issue 4, 2004, Pages 431-441

  Kunkel, Eric J ^a   Plavec, Ivan ^a   Nguyen, Dat ^a   Melrose, Jennifer ^a   Rosler, Elen S ^a   Kao, Leon T ^a   Wang, Yuker ^a   Hytopoulos, Evangelos ^a   Bishop, Anthony C ^b   Bateman, Raynard ^b   Shokat, Kevan M ^b   Butcher, Eugene C ^c   Berg, Ellen L ^a  

^a BioSeek Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; ADAPTOR PROTEIN; APIGENIN; CALCINEURIN INHIBITOR; CELL NUCLEUS RECEPTOR; ENZYME INHIBITOR; GENISTEIN; GLUCOCORTICOID; HEAT SHOCK PROTEIN 90; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOSINATE DEHYDROGENASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; SIGNAL PEPTIDE; SYNAPTOPHYSIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; WORTMANNIN;

AUTOMATION; BIOLOGICAL MODEL; CELL ACTIVATION; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG DESIGN; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; REVIEW; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; ELECTROPORATION; ENDOTHELIUM, VASCULAR; GENE EXPRESSION PROFILING; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RNA, SMALL INTERFERING; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 4644356849     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2004.2.431     Document Type: Review

References (14)

1. Noble ME, Endicott JA, Johnson LN: Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-1805.
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science 2002;298:1912-1934.
3. Kunkel EJ, Dea M, Ebens A, Hytopoulos E, Melrose J, Nguyen D, Ota KS, Plavec I, Wang Y, Watson SR, Butcher EC, Berg EL: An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J 2004;18:1279-1281.
4. Plavec I, Sirenko O, Privat S, Wang Y, Dajee M, Melrose J, Nakao B, Hytopoulos E, Berg EL, Butcher EC: Method for analyzing signaling networks in complex cellular systems. Proc Natl Acad Sci USA 2004;101:1223-1228.
5. Bishop AC: Chemical Genetic Approaches To Highly Selective Protein Kinase Inhibitors. Princeton University, Princeton, NJ, 2000.
6. Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, Han J: Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 1996;271:17920-17926.
7. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ: MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 1996;16: 1247-1255.
8. Tong L, Pav S, White DM, Rogers S, Crane KM, Cywin CL, Brown ML, Pargellis CA: A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol 1997;4:311-316.
9. Wilson KP, McCaffrey PG, Hsiao K, Pazhanisamy S, Galullo V, Bemis GW, Fitzgibbon MJ, Caron PR, Murcko MA, Su MS: The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 1997;4:423-431.
10. Bain J, McLauchlan H, Elliott M, and Cohen P: The specificities of protein kinase inhibitors: an update. Biochem J 2003;371:199-204.
11. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H, Hedge P: Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 1999;6: 559-568.
12. Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Wachter MP, Siekierka JJ: RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 1999;291: 680-687.
13. Borsch-Haubold AG, Pasquet S, Watson SP: Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 1998;273: 28766-28772.
14. Palladino MA, Bahjat FR, Theodorakis EA, and Moldawer LL: Anti-TNFα therapies: The next generation. Nat Rev Drug Discov 2003;2:736-746.